Tag Archives: Bristol Myers Squibb

Sovaldi “Biggest Selling Drug” by 2020

Gilead’s hepatitis C treatment Sovaldi will top the list of biggest selling drugs in 2020, according to UK market intelligence company, Evaluate. “Given its history-making launch, it is no surprise that [Sovaldi] is forecast to become the biggest drug in 2020; the big question will be how long this drug can hang onto the top spot,” […]
Posted in Europe, Gene therapy, Global, Sales, Strategy | Also tagged , , , , , , | Leave a comment

Changing the Hepatitis C Treatment Landscape

The American Journal of Managed Care (AJMC) recently convened an expert panel that analyzed the implications of recommendations by the US Preventive Services Task Force that all Americans born between 1946 and 1964 be screened for the hepatitis C virus (HCV). Widespread screening, along with new therapies that move patients from a chronic condition to […]
Posted in Strategy | Also tagged , | 1 Comment

Bristol-Myers Squibb Sells Diabetes Business to AstraZeneca

Bristol-Myers Squibb has agreed to sell its global diabetes business that was part of its collaboration with AstraZeneca for $2.7 billion with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025. In addition, AstraZeneca will make payments of up to $225 million […]
Posted in Deals, Guest Blog | Also tagged , , | Leave a comment

HIV Market Banking on Fixed-Dose Treatments

The HIV markets are expected to grow for the next two years, but major patent expirations in the following years will have a huge impact on pharmaceutical sales by 2019, according to a new report by DataMonitor. Antiretroviral sales in 2009 were estimated at $11.8 billion. While that figure is forecast to hit $14.4 billion […]
Posted in R&D | Also tagged , , , , , , | Leave a comment

Patient Adherence Awards Winners Revealed

Image via Wikipedia The Center for Business Intelligence, on Monday, revealed winners of its annual Strategic Patient Adherence Awards as part of its two-day conference about patient compliance with their drug regiments. This year’s award winners are: Best Integrated Program—Shire Pharmaceuticals: FOSRENOL ON TRACK Direct To Patient Support Program Best Disease State Program—BMS/Sanofi-Aventis Canada & […]
Posted in Events, Strategy | Also tagged , , , , , , , , | Leave a comment
  • Categories

  • Meta